Biopharmaceutical company, acquired by AstraZeneca in 2007
MedImmune, LLC
Company type
Subsidiary
Industry
Pharmaceutical
Founded
1988; 36 years ago (1988) (as Molecular Vaccines, Inc.) 1989; 35 years ago (1989) (as MedImmune, Inc.)
Headquarters
Gaithersburg, Maryland, U.S.
Products
Synagis FluMist
Parent
AstraZeneca
Website
www.medimmune.com[dead link]
MedImmune, LLC was a wholly owned subsidiary of AstraZeneca before February 14, 2019, when it was announced that the MedImmune name and branding would be discontinued in favor of AstraZeneca.[1][2]
MedImmune was founded in 1988 as Molecular Vaccines, Inc, and was purchased in 2007 for $15.6 billion.[3] Its main offices were located in Gaithersburg, MD, Cambridge, UK, and Mountain View, CA.[4]
It produced Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune acquired FluMist when it purchased Aviron in 2002 for US$ 1.5 billion. FluMist sales totaled US$ 104 million in 2008, US$ 54.8 million in 2007, and US$ 36.4 million in 2006.[5]
FluMist was approved for children two years of age and older in 2007, but initially was approved only for healthy people ages 5 to 49, a significant limitation because it eliminated a significant market—young children who find injections objectionable. Sales of FluMist fell short of analysts' expectations for the first two years the drug was sold. FluMist was initially sold in a frozen form, which was difficult for doctors to store.[6]
MedImmune conducted successful clinical trials for a new generation of FluMist needle-free vaccine, called CAIV-T, which was approved by the U.S. Food and Drug Administration (FDA) in 2007, and is now the form offered on the market.
^"12 years on, Astra draws a line under Medimmune". Evaluate.com. 2019-02-14. Retrieved 2019-02-15.
(anti-IFN-aR) nirsevimab (anti-RSV) MedImmune, Inc. v. Genentech, Inc. "12 years on, Astra draws a line under Medimmune". Evaluate.com. 2019-02-14. Retrieved...
Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). It has its research and development...
patents cover Medimmune's processes for generating the collections of human antibody genes that comprise MedImmune Cambridge libraries. MedImmune has patents...
Tetra in the European Union. FluMist was first introduced in 2003 by MedImmune. The live attenuated influenza vaccine is used to provide protection against...
monoclonal antibody designed for the treatment of cancer. It was developed by MedImmune, and trialed for use in glioblastoma and non-small cell lung cancer. Development...
actual controversy was most recently addressed by the Supreme Court in MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007). But even if an actual controversy...
alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma. Two phase III clinical trials of benralizumab...
designed for the treatment of cancer. It binds to IGF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed...
ulcerative colitis, and Crohn's disease. This drug was developed by MedImmune. World Health Organization (2014). "International Nonproprietary Names...
treatment of Crohn's disease. that targets IL-23. This drug was developed by MedImmune. Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab...
director of the board of Immunocore. She has previously been president at MedImmune and AstraZeneca. She is a council member of the Government–University–Industry...
company, the J. Craig Venter Institute (JCVI), and AstraZeneca (formerly MedImmune). Maryland is home to defense contractor Emergent BioSolutions, which...
and polymyositis. It targets interferon a. Sifalimumab was developed by MedImmune; as of 2017 development had been terminated in favor of moving a competing...
name Imfinzi, is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal...
effect rates were comparable in all groups. The drug was developed by MedImmune, a unit of AstraZeneca, which chose to move anifrolumab instead of sifalimumab...
Wuxi City. That year WuXi AppTec also entered into a joint venture with MedImmune, the biologics arm of AstraZeneca, to co-develop MEDI5117, an anti-IL6...
pneumonia caused by Staphylococcus aureus. This drug was developed by MedImmune World Health Organization (2016). "International Nonproprietary Names...
initiated with this first study completing in 2005. On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate...
acquired companies Astra AB Alexion Pharmaceuticals Cambridge Antibody Technology MedImmune Zeneca People Tom McKillop Louis Schweitzer Category Commons...
pancreatic and colorectal and other cancers. This drug was developed by MedImmune/AstraZeneca. World Health Organization (2016). "International Nonproprietary...
United Therapeutics, Novavax, Emergent BioSolutions, Parabon NanoLabs and MedImmune have headquarters in the region. The area is also home to branch offices...
hemoglobinuria, proteins known as the 'complement system', which is part of the immune system, become overactive because of a genetic mutation and start to attack...
rosuvastatin in lipid management in Chinese patients in Hong Kong". Chin. Med. J. 122 (23): 2814–9. PMID 20092783. Archived from the original on 30 October...
tools of that time (the 1990s). It was developed over a 10-year period by MedImmune Inc. by combining human and mouse DNA. Specifically, antibody production...
Global Information